
Cogstate net sales contracts hit $89M in FY26
- Cogstate completed US$89 million in net sales contracts during the 2026 financial year.
- The company's share price finished down at $2.73 following the business update.
- The growth was driven by an expansion of total contracted future revenue to US$118.5 million.
Cogstate (ASX:CGS) executed US$89 million in full-year net sales contracts, representing a 116% increase over the previous year.
The growth contrasts with the US$41.3 million in net sales contracts executed by the business during the 2025 financial year.
The company stated that net sales contracts for the June quarter alone reached US$21.9 million.
Contracted future revenue entering the 2027 financial year expanded by 32% to US$118.5 million.
Following the announcement, the Cogstate share price was down at $2.73.
Of the contracted future revenue, the company expects to recognise US$48.3 million during the 2027 financial year.
The business noted that its contracted clinical trials revenue for the 2027 financial year reached US$46.1 million.
Frequently asked questions
More from Australia
Sunrise Energy Metals clears FIRB hurdle for Nasdaq move
Elementos starts 3,600m drilling at Cleveland tin project
Dexus Industria chair Jennifer Horrigan retires after 14 years
Anthropic confirms record $81b IPO at $83 a share
dorsaVi signs first French distribution deal
Golden Mile raises $950,000 for Arizona gold drilling